ArticleMaterials today. Bio2026
Rational design of a V-shaped DNA-targeted photosensitizer enables endogenous DNA damage-driven cGAS-STING activation and systemic antitumor immunity.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is a central driver of antitumor immunity, yet its safe and efficient activation in solid tumors remains challenging. Here we report a V-shaped photosensitizer, 2C6, that functions as an in situ DNA-fragmentation agent by directly targeting double-stranded DNA (dsDNA). Owing to its A-π-D-π-A molecular framework, 2C6 exhibits efficient reactive oxygen species (ROS) generation under low-power white-light irradiation. Photoactivation of 2C6 induces concurrent mitochondrial and nuclear DNA damage, leading to the accumulation of oxidized dsDNA fragments in the cytosol, which is closely associated with activation of the cGAS-STING signaling pathway. In parallel, 2C6-PDT induces pyroptosis and immunogenic cell death (ICD), as evidenced by elevated levels of pyroptosis-associated markers (including NLRP3, cleaved caspase-1, and GSDMD), along with features of ICD such as CRT exposure, ATP secretion, and HMGB1 release. In a murine 4T1 triple-negative breast cancer (TNBC) postsurgical residual model, a single intraoperative 2C6-PDT prevented local tumor recurrence, established immune memory within the observation period, and suppressed distant tumor growth and lung metastasis without immunoadjuvants. Collectively, 2C6 couples photoinduced DNA damage to cytosolic dsDNA sensing, type I interferon signaling, and adaptive immune activation through a defined cascade encompassing DNA damage, dsDNA accumulation, cGAS-STING engagement, inflammatory signaling, and immune-cell infiltration. Together, these findings demonstrate that rationally engineered DNA-targeted photosensitizers can convert localized photodynamic tumor ablation into a systemic photoimmunotherapeutic response, providing a strategy to transform immunologically "cold" tumors into immune-responsive states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.